Related Experiment Video
Updated: May 26, 2026
06:35
Alternative Methods for the Detection of Superoxide Anion Generation in Platelets
Published on: March 29, 2024
Platelet oxidative stress and thrombosis.
Francesco Violi1, Pasquale Pignatelli
1I ClinicaMedica, Sapienza University, Roma. francesco.violi@uniroma1.it
Thrombosis Research
|January 3, 2012
Summary
Reactive oxidant species and isoprostanes play a key role in platelet activation. Targeting platelet isoprostane formation with novel antiplatelet drugs, potentially involving polyphenols, is a promising future therapeutic strategy.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Reactive oxidant species (ROS) are implicated in platelet activation.
- Isoprostanes are key mediators in ROS-driven platelet activation.
- Platelet NADPH oxidase is identified as a primary source of platelet ROS and isoprostanes.
Purpose of the Study:
- To explore the role of reactive oxidant species and isoprostanes in platelet activation.
- To investigate the potential of targeting isoprostane formation for antiplatelet therapy.
- To assess the potential of polyphenols as therapeutic agents due to their antioxidant properties.
Main Methods:
- Review of experimental and clinical studies on platelet activation mechanisms.
- Analysis of the role of platelet NADPH oxidase in ROS and isoprostane production.
- Consideration of pharmacologic strategies targeting isoprostane formation.
Main Results:
- Platelet activation is significantly influenced by reactive oxidant species.
- Enhanced isoprostane formation is a major pathway in ROS-mediated platelet activation.
- Platelet NADPH oxidase is the principal source of platelet ROS and isoprostanes.
Conclusions:
- Targeting platelet isoprostane formation presents a potential therapeutic avenue for antiplatelet drugs.
- Polyphenols, owing to their antioxidant properties, warrant investigation for inhibiting platelet aggregation.
- Further interventional trials are necessary to validate the in vivo efficacy of polyphenols in preventing atherosclerotic progression.
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...